AdaptHealth Corp. (NASDAQ:AHCO) Receives $12.10 Average PT from Brokerages

Shares of AdaptHealth Corp. (NASDAQ:AHCO) have been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $12.10.

A number of analysts recently commented on the stock. UBS Group boosted their price objective on shares of AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Truist Financial boosted their price target on AdaptHealth from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Jefferies Financial Group downgraded AdaptHealth from a “buy” rating to a “hold” rating and dropped their price objective for the company from $14.50 to $8.00 in a research note on Monday, January 8th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $13.00 target price on shares of AdaptHealth in a research report on Monday, March 4th.

Insider Transactions at AdaptHealth

In other news, major shareholder James E. Flynn sold 182,607 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the transaction, the insider now directly owns 11,643,769 shares of the company’s stock, valued at $128,314,334.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder James E. Flynn sold 52,487 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $10.93, for a total transaction of $573,682.91. Following the transaction, the insider now owns 11,826,376 shares of the company’s stock, valued at $129,262,289.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder James E. Flynn sold 182,607 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the sale, the insider now owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.

Institutional Trading of AdaptHealth

Several institutional investors have recently made changes to their positions in AHCO. GAMMA Investing LLC lifted its stake in shares of AdaptHealth by 197.1% in the 1st quarter. GAMMA Investing LLC now owns 2,537 shares of the company’s stock valued at $29,000 after purchasing an additional 1,683 shares in the last quarter. Oak Thistle LLC acquired a new stake in AdaptHealth during the 3rd quarter worth approximately $94,000. Campbell & CO Investment Adviser LLC purchased a new position in AdaptHealth in the third quarter valued at approximately $100,000. Raymond James & Associates acquired a new position in AdaptHealth during the third quarter valued at approximately $101,000. Finally, Everence Capital Management Inc. purchased a new stake in AdaptHealth during the fourth quarter worth approximately $102,000. 82.67% of the stock is owned by hedge funds and other institutional investors.

AdaptHealth Price Performance

Shares of AHCO opened at $10.06 on Monday. The firm has a market capitalization of $1.34 billion, a PE ratio of -1.89, a P/E/G ratio of 0.66 and a beta of 1.02. The stock’s 50 day moving average is $10.21 and its two-hundred day moving average is $8.49. AdaptHealth has a twelve month low of $6.37 and a twelve month high of $15.37. The company has a current ratio of 1.21, a quick ratio of 1.00 and a debt-to-equity ratio of 1.44.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. The firm had revenue of $858.23 million for the quarter, compared to analyst estimates of $825.94 million. Research analysts anticipate that AdaptHealth will post 0.88 earnings per share for the current year.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.